Table 3 Antimicrobial resistance to commonly used topical agents among bacterial isolates from patients with ophthalmic infections, London, 2009–2015. #One isolate was ‘intermediate’. Fusidic acid resistance increased significantly from secondary to tertiary care (p < 0.01). Chloramphenicol resistance increased significantly from primary to tertiary care (p < 0.01). ^ including Pseudomonas spp., Chryseobacterium spp. ~ including Pseudomonas spp. * including enterococci and all Gram-negative pathogens (except Neisseria spp. and Moraxella spp.) [14, 15]
From: Antibacterial resistance in ophthalmic infections: a multi-centre analysis across UK care settings
Antimicrobial | Descriptor | Care setting | ||
|---|---|---|---|---|
Primary | Secondary | Tertiary | ||
Chloramphenicol | Intrinsically-resistant isolates^ (n) | 5.6% (82) | 7.8% (58) | 27.2% (127) |
Non-intrinsically resistant isolates undergoing susceptibility testing (n) | 94.0% (1301) | 91.7% (632) | 71.2% (242) | |
Non-intrinsically resistant isolates found to be resistant (n) | 7.0% (91) | 8.7% (55) | 12.8% (31) | |
Overall antimicrobial resistance | 11.8% | 15.1% | 33.8% | |
Moxifloxacin | Intrinsically-resistant isolates~ (n) | 5.5% (81) | 7.6% (57) | 25.5% (118) |
Non-intrinsically resistant isolates undergoing susceptibility testing (n) | 12.5% (173) | 7.2% (50) | 10.9% (38) | |
Non-intrinsically resistant isolates found to be resistant (n) | 0% (0) | 0% (0) | 0% (0#) | |
Overall percentage resistance | 5.5% | 7.6% | 25.5% | |
Fusidic acid | Intrinsically-resistant isolates* (n) | 46.9% (688) | 49.7% (371) | 50.3% (235) |
Non-intrinsically resistant isolates undergoing susceptibility testing (n) | 55.1% (429) | 66.2% (249) | 72.0% (167) | |
Non-intrinsically resistant isolates found to be resistant (n) | 8.9% (38) | 11.2% (28) | 23.4% (39) | |
Overall percentage resistance | 49.6% | 53.4% | 58.7% | |